Mutya JD - Vyne Therapeutics Chief Counsel
| VYNE Stock | USD 2.36 0.34 12.59% |
Insider
Mutya JD is Chief Counsel of Vyne Therapeutics
| Age | 50 |
| Address | 685 Route 202/206 N, Bridgewater, NJ, United States, 08807 |
| Phone | 800 775 7936 |
| Web | https://www.vynetherapeutics.com |
Vyne Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3454) % which means that it has lost $0.3454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6047) %, meaning that it created substantial loss on money invested by shareholders. Vyne Therapeutics' management efficiency ratios could be used to measure how well Vyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 30, 2025, Return On Tangible Assets is expected to decline to -0.35. In addition to that, Return On Capital Employed is expected to decline to -0.39. At present, Vyne Therapeutics' Net Tangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.9 M, whereas Total Current Assets are forecasted to decline to about 78.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Chester III | Revelation Biosciences | 45 | |
| Jason Cavalier | Lyra Therapeutics | 52 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| Donald MBA | Lyra Therapeutics | 70 | |
| Melissa BradfordKlug | Akari Therapeutics PLC | 54 | |
| Miles Nunn | Akari Therapeutics PLC | 56 | |
| Marni Kottle | Kronos Bio | N/A | |
| Margaret MD | Pulmatrix | 67 | |
| Marc Stapley | Veracyte | 55 | |
| James Balkovec | Cidara Therapeutics | N/A | |
| James CPA | Longeveron LLC | 58 | |
| Daniela Santiesteban | Salarius Pharmaceuticals | N/A | |
| Stephanie Yao | Kronos Bio | N/A | |
| Annie McGuire | Veracyte | 45 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Mark Newman | GeoVax Labs | 70 | |
| MBA CMA | Pulmatrix | 70 | |
| MD FACC | Longeveron LLC | 62 | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| KwanHong MD | Longeveron LLC | 57 | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.35 |
Vyne Therapeutics Leadership Team
Elected by the shareholders, the Vyne Therapeutics' board of directors comprises two types of representatives: Vyne Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vyne. The board's role is to monitor Vyne Therapeutics' management team and ensure that shareholders' interests are well served. Vyne Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vyne Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Russell DPhil, VP Devel | ||
| Iain Stuart, Chief Officer | ||
| MS MD, Consultant | ||
| Subhashis MD, Senior Development | ||
| David Domzalski, President CEO | ||
| David Schuz, VP Property | ||
| Faad MD, Consultant | ||
| Tyler Zeronda, Principal CFO | ||
| MD FAAD, Consultant | ||
| Tyler CPA, CFO Treasurer | ||
| Mutya JD, Chief Counsel |
Vyne Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vyne Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (52.51) % | ||||
| Current Valuation | (33.18 M) | ||||
| Shares Outstanding | 14.75 M | ||||
| Shares Owned By Insiders | 8.31 % | ||||
| Shares Owned By Institutions | 56.03 % | ||||
| Number Of Shares Shorted | 112.33 K | ||||
| Price To Book | 0.58 X | ||||
| Price To Sales | 74.80 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share | Quarterly Revenue Growth 0.467 | Return On Assets | Return On Equity |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.